Fulltext

Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hämatologie und Onkologie OSHO-53 phase II study

Kiefer, T. ; Hirt, C. ; Späth, C. ; Schüler, F. ; Al-Ali, H. K. ; Wolf, H.-H ; Herbst, R. ; Maschmeyer, G. ; Helke, K. ; Kessler, C. ; Niederwieser, D. ; Busemann, C. ; Schroeder, H. ; Vogelgesang, S. ; Kirsch, M. ; Montemurro, M. ; Krüger, W. H. ; Dölken, G.

In: Annals of Oncology, 2012, vol. 23, no. 7, p. 1809-1812

Aggiungi alla tua lista
    Titre
    • Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hämatologie und Onkologie OSHO-53 phase II study
    Auteur
    • Kiefer, T.. Department of Internal Medicine C, Haematology and Oncology, Stem Cell Transplantation, Ernst Moritz Arndt University, Greifswald
    • Hirt, C.. Department of Internal Medicine C, Haematology and Oncology, Stem Cell Transplantation, Ernst Moritz Arndt University, Greifswald
    • Späth, C.. Department of Internal Medicine C, Haematology and Oncology, Stem Cell Transplantation, Ernst Moritz Arndt University, Greifswald
    • Schüler, F.. Division of Haematology and Oncology, University of Leipzig, Leipzig
    • Al-Ali, H. K.. Division of Haematology and Oncology, University of Leipzig, Leipzig
    • Wolf, H.-H. Department of Internal Medicine IV, Haematology and Oncology, Martin-Luther-Universität Halle-Wittenberg, Halle/Saale
    • Herbst, R.. Department of Haematology and Oncology/Bone Marrow Transplantation, Chemnitz Hospital, Chemnitz
    • Maschmeyer, G.. Department of Haematology, Oncology and Palliative Care, Hospital Ernst von Bergmann, Potsdam
    • Helke, K.. Departments of Radiotherapy
    • Kessler, C.. Neurology
    • Niederwieser, D.. Division of Haematology and Oncology, University of Leipzig, Leipzig
    • Busemann, C.. Department of Internal Medicine C, Haematology and Oncology, Stem Cell Transplantation, Ernst Moritz Arndt University, Greifswald
    • Schroeder, H.. Neurosurgery
    • Vogelgesang, S.. Neuropathology
    • Kirsch, M.. Diagnostic Radiology and Neuroradiology, Ernst Moritz Arndt University, Greifswald, Germany
    • Montemurro, M.. Comprehensive Cancer Center, University Hospital Lausanne (Centre Hospitalier Universitaire Vaudois), Lausanne, Switzerland
    • Krüger, W. H.. Department of Internal Medicine C, Haematology and Oncology, Stem Cell Transplantation, Ernst Moritz Arndt University, Greifswald
    • Dölken, G.. Department of Internal Medicine C, Haematology and Oncology, Stem Cell Transplantation, Ernst Moritz Arndt University, Greifswald
    Type de document
    • Postprint
    Langue
    • Inglese
    Publié dans
    • Annals of Oncology, 2012, vol. 23, no. 7, p. 1809-1812. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:300121
    Summary
    Background We previously reported the results of a phase II study for patients with newly diagnosed primary central nervous system lymphoma treated with autologous peripheral blood stem-cell transplantation (aPBSCT) and response-adapted whole-brain radiotherapy (WBRT). Now, we update the initial results. Patients and methods From 1999 to 2004, 23 patients received high-dose methotrexate. In case of at least partial remission, high-dose busulfan/thiotepa (HD-BuTT) followed by aPBSCT was carried out. Patients refractory to induction or without complete remission after HD-BuTT received WBRT. Eight patients still alive in 2011 were contacted and Mini-Mental State Examination (MMSE) and the European Organisation for Research and Treatment of Cancer quality-of-life questionnaire (QLQ)-C30 were carried out. Results Of eight patients still alive, median follow-up is 116.9 months. Only one of nine irradiated patients is still alive with a severe neurologic deficit. In seven of eight patients treated with HD-BuTT, health condition and quality of life are excellent. MMSE and QLQ-C30 showed remarkably good results in patients who did not receive WBRT. All of them have a Karnofsky score of 90%-100%. Conclusions Follow-up shows an overall survival of 35%. In six of seven patients where WBRT could be avoided, no long-term neurotoxicity has been observed and all patients have an excellent quality of life